Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02419677

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases

Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases

Sponsor: The First People's Hospital of Changzhou

Conditions Colorectal Cancer

Interventions Cytokine-induced killer cells Radiofrequency ablation

Updated 5 times since 2017 Last updated: Apr 14, 2015 Started: Jan 31, 2010 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Colorectal Cancer and is currently completed. The First People's Hospital of Changzhou leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First People's Hospital of Changzhou

Data source: The First People's Hospital of Changzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changzhou, China